We provide evidence that the PARP inhibitor AZD2281 inhibits the growth of breast cancer cells with BRCA1 allelic loss lacking mutation in BRCA1. These results might lead the way to new approaches for treating a broad spectrum of breast cancer subtypes. Here, BRCA1 is linked to breast cancer.